blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3126364

EP3126364 - MACROCYLIC PYRIMIDINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.12.2018
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  05.01.2018
FormerGrant of patent is intended
Status updated on  04.09.2017
FormerRequest for examination was made
Status updated on  06.01.2017
FormerThe international publication has been made
Status updated on  07.11.2016
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
Janssen Pharmaceutica, N.V.
Turnhoutseweg 30
2340 Beerse / BE
[2017/06]
Inventor(s)01 / DIELS, Gaston, Stanislas, Marcella
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
02 / SCHOENTJES, Bruno
Janssen-Cilag 1 Rue Camille Desmoulins
Issy-les-Moulineaux
F-92130 Ile-de-France / FR
03 / VERSELE, Matthias, Luc, Aimé
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
04 / BERTHELOT, Didier, Jean-Claude
Janssen-Cilag Campus de Maigremont
CS 10615
F-27100 Val de Reuil / FR
05 / WILLEMS, Marc
Merellaan 46
B-2350 Vosselaar / BE
06 / VIELLEVOYE, Marcel
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
07 / EMBRECHTS, Werner, Constant, Johan
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
08 / WROBLOWSKI, Berthold
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
09 / MEERPOEL, Lieven
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
 [2017/06]
Representative(s)Lenaerts, Philip
Johnson & Johnson Patent Law Department
Turnhoutseweg 30
2340 Beerse / BE
[2017/06]
Application number, filing date15713522.902.04.2015
[2017/06]
WO2015EP57399
Priority number, dateEP2014016344303.04.2014         Original published format: EP 14163443
EP2014018374705.09.2014         Original published format: EP 14183747
[2017/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015150555
Date:08.10.2015
Language:EN
[2015/40]
Type: A1 Application with search report 
No.:EP3126364
Date:08.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 08.10.2015 takes the place of the publication of the European patent application.
[2017/06]
Type: B1 Patent specification 
No.:EP3126364
Date:07.02.2018
Language:EN
[2018/06]
Search report(s)International search report - published on:EP08.10.2015
ClassificationIPC:C07D471/22, C07D498/22, A61K31/505, A61P35/00
[2017/06]
CPC:
C07D471/22 (EP,IL,KR,US); A61K31/505 (KR); A61K31/519 (KR);
A61P1/04 (EP); A61P13/08 (EP); A61P15/00 (EP);
A61P25/00 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P35/00 (EP); A61P43/00 (EP); C07D498/22 (EP,US);
Y02P20/582 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/06]
Extension statesBA03.11.2016
ME03.11.2016
Validation statesMA03.11.2016
TitleGerman:MAKROCYCLISCHE PYRIMIDINDERIVATE[2017/06]
English:MACROCYLIC PYRIMIDINE DERIVATIVES[2017/06]
French:DÉRIVÉS DE PYRIMIDINE BICYCLE[2017/36]
Former [2017/06]DÉRIVÉS DE PYRIMIDINE MACROCYCLIQUES
Entry into regional phase03.11.2016National basic fee paid 
03.11.2016Designation fee(s) paid 
03.11.2016Examination fee paid 
Examination procedure04.10.2016Date on which the examining division has become responsible
03.11.2016Examination requested  [2017/06]
13.04.2017Amendment by applicant (claims and/or description)
05.09.2017Communication of intention to grant the patent
21.12.2017Fee for grant paid
21.12.2017Fee for publishing/printing paid
21.12.2017Receipt of the translation of the claim(s)
Opposition(s)08.11.2018No opposition filed within time limit [2019/03]
Fees paidRenewal fee
02.05.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.04.2015
AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
MK07.02.2018
NL07.02.2018
PL07.02.2018
PT07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
TR07.02.2018
LU02.04.2018
MT02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
[2020/31]
Former [2020/30]HU02.04.2015
AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
PT07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
TR07.02.2018
LU02.04.2018
MT02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2020/28]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
PT07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
TR07.02.2018
LU02.04.2018
MT02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2020/16]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
TR07.02.2018
LU02.04.2018
MT02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2020/08]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
LU02.04.2018
MT02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2019/13]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SI07.02.2018
SK07.02.2018
SM07.02.2018
LU02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2019/08]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SK07.02.2018
SM07.02.2018
LU02.04.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/52]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
MC07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SK07.02.2018
SM07.02.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/51]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
DK07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SK07.02.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/50]AL07.02.2018
AT07.02.2018
CY07.02.2018
CZ07.02.2018
EE07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
NL07.02.2018
PL07.02.2018
RO07.02.2018
RS07.02.2018
SK07.02.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/46]AL07.02.2018
AT07.02.2018
CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
NL07.02.2018
PL07.02.2018
RS07.02.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/40]AT07.02.2018
CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
NL07.02.2018
PL07.02.2018
RS07.02.2018
BG07.05.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/39]AT07.02.2018
CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
LV07.02.2018
NL07.02.2018
PL07.02.2018
RS07.02.2018
NO07.05.2018
GR08.05.2018
IS07.06.2018
Former [2018/37]CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
NL07.02.2018
PL07.02.2018
NO07.05.2018
GR08.05.2018
Former [2018/36]CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
NL07.02.2018
PL07.02.2018
NO07.05.2018
Former [2018/35]CY07.02.2018
FI07.02.2018
HR07.02.2018
LT07.02.2018
NL07.02.2018
NO07.05.2018
Cited inInternational search[AD]WO2009112439  (JANSSEN PHARMACEUTICA NV [BE], et al) [AD] 1-15 * compounds 2,148,14,4,85 *;
 [A]  - ANDERS POULSEN ET AL, "Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)", JOURNAL OF MOLECULAR MODELING, SPRINGER, DE, (20120722), vol. 19, no. 1, doi:10.1007/S00894-012-1528-7, ISSN 0948-5023, pages 119 - 130, XP035158034 [A] 1-15 * page 119; table 1; compound 14 *

DOI:   http://dx.doi.org/10.1007/s00894-012-1528-7
 [A]  - ASHWINI K. DEVKOTA ET AL, "Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact", BIOCHEMISTRY, (20120313), vol. 51, no. 10, doi:10.1021/bi201787p, ISSN 0006-2960, pages 2100 - 2112, XP055121644 [A] 1-15 * page 2100, paragraph 1st *

DOI:   http://dx.doi.org/10.1021/bi201787p
by applicantWO2004084898
 WO2004105765
 WO2005058318
 WO2005058913
 WO2006061415
 WO2006061417
 WO2007003525
 WO2008155421
 WO2009016132
 WO2009026197
 WO2009112439
 WO2011008788
 WO2011051282
    - BROWNE ET AL., EUR J BIOCHEM., (2002), vol. 269, no. 22, pages 5360 - 5368
    - LEPRIVIER ET AL., CELL, (2013), vol. 153, no. 5, pages 1064 - 1079
    - HAIT ET AL., CLIN CANCER RES., (2006), vol. 12, pages 1961 - 1965
    - JIN ET AL., J CELL SCI., (2007), vol. 120, no. 3, pages 379 - 83
    - KAVALALI ET AL., AM J PSYCHIATRY, (2012), vol. 169, no. 11, pages 1150 - 1156
    - AMARAVADI ET AL., CLIN CANCER RES., (2011), vol. 17, pages 654 - 666
    - BEN-ZVI ET AL., CLIN REV ALLERGY IMMUNOL., (2012), vol. 42, no. 2, pages 145 - 53
    - MAIURI ET AL., CELL DEATH DIFFER., (2009), vol. 16, no. 1, pages 87 - 93
    - BURGER ET AL., MEDICINAL CHEMISTRY LETTERS, (2011), vol. 2, no. 1, pages 34 - 38
    - JOURNAL OF MEDICINAL CHEMISTRY, (1994), vol. 37, no. 9, pages 1362 - 70
    - JOURNAL OF ANTIBIOTICS, (1984), vol. 37, no. 5, pages 532 - 45
    - JOURNAL OF MEDICINAL CHEMISTRY, (2009), vol. 52, no. 23, pages 7503 - 7511
    - JOURNAL OF ORGANIC CHEMISTRY, (2002), vol. 67, no. 21, pages 7541 - 7543
    - BIOORGANIC & MEDICINAL CHEMISTRY, (2002), vol. 10, pages 1595 - 1610
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.